56 related articles for article (PubMed ID: 33823685)
1. Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
Wong WB; Seetasith A; Hung A; Zullig LL
PLoS One; 2023; 18(1):e0280570. PubMed ID: 36656871
[TBL] [Abstract][Full Text] [Related]
2. Association of State Insulin Out-of-Pocket Caps With Insulin Cost-Sharing and Use Among Commercially Insured Patients With Diabetes : A Pre-Post Study With a Control Group.
Garabedian LF; Zhang F; Costa R; Argetsinger S; Ross-Degnan D; Wharam JF
Ann Intern Med; 2024 Apr; 177(4):439-448. PubMed ID: 38527286
[TBL] [Abstract][Full Text] [Related]
3. Higher Out-of-pocket Expenses are Associated with Worse Health-related Quality of Life in Burn Survivors: A Northwest Regional Burn Model System Investigation.
Sheckter CC; Holan C; Carrougher G; Orton C; Gibran N; Stewart BT
J Burn Care Res; 2023 Nov; 44(6):1349-1354. PubMed ID: 37094279
[TBL] [Abstract][Full Text] [Related]
4. Hospice use and end-of-life care among older patients with esophageal cancer.
Tramontano AC; Nipp R; Kong CY; Yerramilli D; Gainor JF; Hur C
Health Sci Rep; 2018 Sep; 1(9):e76. PubMed ID: 30623099
[TBL] [Abstract][Full Text] [Related]
5. Impact of age, comorbidity, and polypharmacy on receipt of systemic therapy in advanced cancers: A retrospective population-based study.
Rittberg R; Decker K; Lambert P; Bravo J; St John P; Turner D; Czaykowski P; Dawe DE
J Geriatr Oncol; 2024 Mar; 15(2):101689. PubMed ID: 38219331
[TBL] [Abstract][Full Text] [Related]
6. Association between oral targeted cancer drug net health benefit, uptake, and spending.
Lau-Min KS; Wu Y; Rochester S; Bekelman JE; Kanter GP; Getz KD
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38745430
[TBL] [Abstract][Full Text] [Related]
7. Impact of time of diagnosis on out-of-pocket costs of cancer treatment, a side effect of health insurance design in Australia.
Naghsh-Nejad M; van Gool K
Health Policy; 2024 Mar; ():105055. PubMed ID: 38760250
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and trends in polypharmacy and excessive polypharmacy: a retrospective national database analysis (2012-2021).
Van der Linden L; Tournoy J
Int J Clin Pharm; 2024 May; ():. PubMed ID: 38704778
[TBL] [Abstract][Full Text] [Related]
9. Treatment sequences and drug costs from diagnosis to death in multiple myeloma.
Seefat MR; Cucchi DGJ; Groen K; Donker ML; van der Hem KG; Westerman M; Gerrits AM; Beeker A; van de Donk NWCJ; Blommestein HM; Zweegman S
Eur J Haematol; 2024 Mar; 112(3):360-366. PubMed ID: 37821211
[TBL] [Abstract][Full Text] [Related]
10. Cancer treatment at the end of life in older patients.
Lichtman SM
Ann Transl Med; 2020 Jul; 8(14):895. PubMed ID: 32793739
[No Abstract] [Full Text] [Related]
11. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
12. Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims.
Vyas A; Descoteaux A; Kogut S; Parikh MA; Campbell PJ; Green A; Westrich K
J Manag Care Spec Pharm; 2022 Aug; 28(8):831-844. PubMed ID: 35876294
[No Abstract] [Full Text] [Related]
13. Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.
Bao Y; Maciejewski RC; Garrido MM; Shah MA; Maciejewski PK; Prigerson HG
J Pain Symptom Manage; 2018 Apr; 55(4):1113-1121.e3. PubMed ID: 29241809
[TBL] [Abstract][Full Text] [Related]
14. Patient out-of-pocket spending in cranial neurosurgery: single-institution analysis of 6569 consecutive cases and literature review.
Yoon S; Mooney MA; Bohl MA; Sheehy JP; Nakaji P; Little AS; Lawton MT
Neurosurg Focus; 2018 May; 44(5):E6. PubMed ID: 29712524
[TBL] [Abstract][Full Text] [Related]
15. Polypharmacy, chemotherapy receipt, and medication-related out-of-pocket costs at end of life among commercially insured adults with advanced cancer.
McDermott CL; Curtis JR; Sun Q; Fedorenko C; Kreizenbeck K; Ramsey SD
J Oncol Pharm Pract; 2022 Jun; 28(4):836-841. PubMed ID: 33823685
[TBL] [Abstract][Full Text] [Related]
16. Out-of-pocket cost by cancer stage at diagnosis in commercially insured patients in the United States.
McGarvey N; Gitlin M; Fadli E; Chung KC
J Med Econ; 2023; 26(1):1318-1329. PubMed ID: 37907436
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
